How Investors Are Reacting To Bristol Myers Squibb (BMY) R&D Leadership Overhaul
Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.
BMS sets unified research and development structure for 2027
Bristol Myers Squibb (BMY) Stock Looks Below Fair Value Following A 41% Run
Bristol Myers research chief to depart in ‘evolution’ of company’s structure
Bristol Myers Squibb Announces Evolution of Research & Development Organization
Our Bristol Myers Squibb Stock Pick Is Up 35%. It’s Still a Good Bet in Healthcare.
Bristol Myers Squibb Appoints Cristian Massacesi To Lead A Unified, End-To-End R&D Organization, Effective January 1, 2027
Bristol Myers Squibb (BMY) Reports 56 Week Pediatric Phase 3 Camzyos Data
Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors
Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
Bristol Myers Squibb Presents 56-Week Results From Phase 3 SCOUT-HCM Clinical Trial In Late-Breaker Presentation At HCMS Scientific Sessions
Bristol Myers Squibb (BMY) Expands Neuroscience Push With Multi Year AI Alliance
Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Rally Already Priced In?
Polaris Rx Selected by Bristol Myers Squibb to Dispense ZENBEXUS™ (iberdomide), the First FDA-Approved CELMoD Therapy for Multiple Myeloma
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol-Myers Squibb (NYSE:BMY) Breakout Setup Backed by Technical Strength
BMY Q3 deep dive: pipeline advances offset margin pressure as guidance shifts
5 must-read analyst questions from Bristol-Myers Squibb’s Q3 earnings call
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.